Home › Migraine › Nevada › Las Vegas
Migraine clinical trials in Las Vegas, NV
3 studies for Migraine are looking for participants at sites in and around Las Vegas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
RecruitingPhase 3
- Oasis Clinical Research, Las Vegas
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
RecruitingPhase 3
- IMA Clinical Research - Las Vegas, Las Vegas
- Excel Clinical Research, Las Vegas
- Wake Research Las Vegas Rainbow, Las Vegas
- and 2 more
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
RecruitingPhase 2
- M3 Wake Research - Las Vegas Rainbow, Las Vegas
About Migraine
Migraines are pulsing or throbbing headaches in one area of the head. Learn about other symptoms, what triggers migraines, and how to treat them.
More about Migraine on MedlinePlus
Migraine trials in other cities
- Cincinnati, OH12 studies
- Omaha, NE9 studies
- Austin, TX9 studies
- Aurora, CO8 studies
- Miami, FL8 studies
- Stamford, CT8 studies
- Atlanta, GA8 studies
- Washington, DC8 studies
- Phoenix, AZ7 studies
- Philadelphia, PA7 studies
- Tampa, FL7 studies
- San Diego, CA7 studies
Other studies in Las Vegas
- Obesity21 studies
- Overweight19 studies
- Type 2 Diabetes17 studies
- Major Depressive Disorder13 studies
- Breast Cancer11 studies
- Non-Small Cell Lung Cancer10 studies
- Cancer (all types)9 studies
- Metastatic Cancer8 studies
- Colorectal Cancer8 studies
- Schizophrenia7 studies
- Prostate Cancer7 studies
- Alzheimer's Disease7 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.